Publication type
Report
Author
Publication date
January 16, 2026
Summary:
The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:
ADVICE: following a full submission sotatercept (Winrevair®) is not recommended for use within NHSScotland.
Indication under review: in combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with WHO Functional Class (FC) II to III, to improve exercise capacity.
In a phase III study of patients with PAH with WHO FC II or III who were receiving stable background therapy, sotatercept significantly improved exercise capacity, measured by the 6-minute walk test, compared with placebo.
The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
The submitting company has indicated their intention to make a resubmission.
Subjects
Link
https://scottishmedicines.org.uk/media/9785/sotatercept-winrevair-final-jan-2026-for-website.pdf
Notes
References: Pennington, B.M., Alava, M.H., and Strong, M. (2025) 'Unpaid caring and heath-related quality of life: longitudinal analysis of Understanding Society (the UK Household Longitudinal Survey)', Value in Health, 28(1):138-147. https://doi.org/10.1016/j.jval.2024.08.004
#589068